Meanwhile, the BSE Sensex was up 221.76 points, or 1.22% to 18,375.75.
On BSE, 4,115 shares were traded in the counter as against average daily volume of 54,057 shares in the past one quarter.
The stock opened with an upward gap, surging by the maximum 5% daily circuit and remained locked at the 5% level so far in the day. The stock had hit a 52-week high of Rs 62.50 on 16 November 2011. The stock had hit a 52-week low of Rs 26.10 on 21 December 2011.
The small-cap stock had outperformed the market over the past one month till 16 February 2012, rising 13.33% compared with the Sensex's 12.14% gain. The scrip had, however, underperformed the market in past one quarter, falling 39.93% as against Sensex's 8.21% gain.
The company has an equity capital of Rs 65.77 crore. Face value per share is Rs 10.
The Transgene Biotek stock has surged 10.18% in two trading sessions from Rs 32.40 on Wednesday, 15 February 2012, after the company announced stellar Q3 earnings after market hours on Wednesday, 15 February 2012. The stock had jumped by the maximum permissible level of 5% to settle at Rs 34 on Thursday, 16 February 2012.
Transgene Biotek's net profit galloped 31360% to Rs 15.73 crore on 762.6% growth in net sales to Rs 8.54 crore in Q3 December 2011 over Q3 December 2010. The company said that there was exceptional income of Rs 13.09 crore in Q3 December 2011, which represents gain due to foreign exchange fluctuations.
Transgene Biotek is engaged in the research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for the qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.